VRNA

Verona Pharma plc [VRNA] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

VRNA Stock Summary

Top 10 Correlated ETFs

VRNA

Top 10 Correlated Stocks

VRNA

In the News

VRNA Financial details

Company Rating
-
Market Cap
1.28B
Income
-54.49M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
79
Optionable
No
Shortable
Yes
Earnings
07 May 2024
P/E
-237.1
Forward P/E
-
PEG
70.45
P/S
3122.13
P/B
45.6
P/C
-
P/FCF
-30.07
Quick Ratio
29.61
Current Ratio
30.68
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.69
EPS next Y
-
EPS next Q
-
EPS this Y
-33.65%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-26.33%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
28.24%
SMA50
38.96%
SMA100
74.19%
Inst Own
-
Inst Trans
-
ROA
-17%
ROE
-19%
ROC
-0.22%
Gross Margin
24%
Oper. Margin
-13351%
Profit Margin
-11067%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
11.83-23.81
52W High
+300.87%
52W Low
+738.18%
RSI
78.04
Rel Volume
1.65
Avg Volume
443.31K
Volume
733.02K
Perf Week
9.79%
Perf Month
27.59%
Perf Quarter
130.15%
Perf Half Y
130.73%
-
-
-
-
Beta
0.415
-
-
Volatility
3.26%, 8.13%
Prev Close
-0.32%
Price
92.2
Change
2.38%

Something similar

Top by Market Cap
LLY.SW
BRYN.DE
VTI
TSLA
DHR-PB
Top Correlated ETFs
WDIV
FID
HYLA.L
FGD
PDN
Top Correlated Stocks
AGIO
ASMB
SAA.L
ORNBV.HE
2325.T
Similar Market Cap
HBRL.L
002822.SZ
GUSA
0050.HK
SBACX

Company Profile

Healthcare Biotechnology
  • Volume Average 443.31K
  • Market Capitalization 1.28B
  • Employee 79
  • CEO Dr. David S. Zaccardelli Pharm.D.
  • Headquarters London,GB
  • IPO Date 2017-04-28
  • Website https://www.veronapharma.com

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.